Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A bio-engineered rubella E1 antigen.

G M Terry1, L Ho-Terry, P Londesborough

  • 1Department of Chemical Pathology, Faculty of Clinical Sciences, University College, London, England.

Archives of Virology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.

British journal of cancer·2006
Same author

The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions.

British journal of cancer·2004
Same author

Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions.

British journal of cancer·2002
Same author

Detection of high-risk HPV types by the hybrid capture 2 test.

Journal of medical virology·2001
Same author

The construction of defective interfering rubella virus particles.

Archives of virology·2000
Same author

Dopamine release in the amygdaloid complex of the rat, studied by brain microdialysis.

Neuroscience letters·1998
Same journal

Molecular epidemiological investigation of viruses in Amur tigers in Northeast China.

Archives of virology·2026
Same journal

Mining viruses in public databases unveils the diversity within the Deltaflexiviridae family.

Archives of virology·2026
Same journal

Identification of novel hepaciviruses in rock pigeon (Columba livia [Gmelin, 1789]), rusty-margined flycatcher (Myiozetetes cayanensis [Linnaeus, 1766]), and Hispaniolan amazon (Amazona ventralis [Statius Muller, 1776]).

Archives of virology·2026
Same journal

Structural insights into DENV-2 NS2B-NS3 protease and inhibition by glutathione-coated gold nanocluster.

Archives of virology·2026
Same journal

Genomic characterization of three novel Shiga toxin-producing Escherichia coli lytic phages.

Archives of virology·2026
Same journal

Molecular characterization of a novel partitivirus isolated from Fusarium solani, the causal agent of tobacco root rot.

Archives of virology·2026
See all related articles

Researchers created bioengineered rubella E1 proteins for improved diagnostics and vaccines. These proteins demonstrate rubella virus antigenicity without requiring complex glycosylation, simplifying rubella infection detection and potential immunization strategies.

Area of Science:

  • Virology
  • Immunology
  • Biotechnology

Background:

  • Rubella virus is a significant human pathogen.
  • The E1 envelope protein is crucial for rubella virus infectivity and immunogenicity.
  • Developing efficient diagnostic tools and vaccines for rubella remains important.

Purpose of the Study:

  • To bioengineer rubella virus E1 protein and a specific segment (amino acids 207-353) as fusion proteins.
  • To assess the antigenicity of these engineered proteins.
  • To explore their utility in rubella infection diagnosis and experimental immunization.

Main Methods:

  • Expression of E1 fusion proteins in Escherichia coli.
  • Utilizing Staphylococcus aureus protein A for fusion.
  • Characterization of antigenicity using monoclonal antibodies.

Related Experiment Videos

  • Evaluation in immunoassays and animal models.

    • Main Results:

    • Successfully expressed E1 and E1 (207-353) fusion proteins.
    • Confirmed E1-specific antigenicity, independent of glycosylation.
    • Demonstrated the potential of these antigens in diagnostic immunoassays.
    • Showcased their use in experimental immunization.

    Conclusions:

    • Bioengineered rubella E1 proteins retain essential antigenicity.
    • Correct glycosylation is not essential for E1 antigenicity.
    • These engineered antigens offer promising applications for rubella diagnostics and vaccine development.